Bilateral Subcapsular Cataract in A Patient with Crohn's Disease Taking Oral Budesonide Therapy: A Case Report
Budesonide and Cataract
Abstract views: 129 / PDF downloads: 88
DOI:
https://doi.org/10.5281/zenodo.10019776Keywords:
Budesonide, Crohn's disease, cataractAbstract
Crohn's disease is a chronic, inflammatory disease of the gastrointestinal tract, which can progress with remission and flares. In order to maintain remission, initially; systemic glucocorticoids such as prednisolone are used. However, since these traditional glucocorticoids have too many side effects, second-generation drugs such as budesonide, which has much fewer systemic side effects, are now used. However, in the case we presented, a bilateral posterior subcapsular cataract developed in a Crohn's patient followed up with oral budesonide therapy. It was seen that there was no such case report in the literature.
References
Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29(6):643-653. doi:10.1111/j.1365-2036.2008.03891.x
Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97(4):803-823. doi:10.1111/j.1572-0241.2002.05596.x
Miehlke S, Acosta MB, Bouma G, et al. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician [published online ahead of print, 2018 Mar 30]. J Gastroenterol Hepatol. 2018;10.1111/jgh.14151. doi:10.1111/jgh.14151
Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn's disease. Therap Adv Gastroenterol. 2022;15:17562848221078456. Published 2022 Feb 17. doi:10.1177/17562848221078456
Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331(13):842-845. doi:10.1056/NEJM199409293311304
Moja L, Danese S, Fiorino G, Del Giovane C, Bonovas S. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. Aliment Pharmacol Ther. 2015;41(11):1055-1065. doi:10.1111/apt.13190
Delbarre M, Froussart-Maille F. Sémiologie et formes cliniques de la cataracte chez l’adulte [Signs, symptoms, and clinical forms of cataract in adults]. J Fr Ophtalmol. 2020;43(7):653-659. doi:10.1016/j.jfo.2019.11.009.
Yan H, Tan X, Yu J, et al. The occurrence timeline of steroid-induced ocular hypertension and cataract in children with systemic autoimmune diseases. Int Ophthalmol. 2022;42(7):2175-2184. doi:10.1007/s10792-022-02217-5
Kačmař J, Cholevík D. Corticosteroid Induced Posterior Subcapsular Cataract. KORTIKOSTEROIDY INDUKOVANÁ ZADNÍ SUBKAPSULÁRNÍ KATARAKTA. Cesk Slov Oftalmol. 2019;74(6):226-232. doi:10.31348/2018/6/2
Abuekteish F, Kirkpatrick JN, Russell G. Posterior subcapsular cataract and inhaled corticosteroid therapy. Thorax. 1995;50(6):674-676. doi:10.1136/thx.50.6.674
Simons FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet. 1993;342(8874):776-778. doi:10.1016/0140-6736(93)91541-s
Schlenker MB, Thiruchelvam D, Redelmeier DA. Association of Cataract Surgery With Traffic Crashes. JAMA Ophthalmol. 2018;136(9):998-1007. doi:10.1001/jamaophthalmol.2018.2510
Good WV. Cataract surgery in young children. Br J Ophthalmol. 2001;85(3):254. doi:10.1136/bjo.85.3.254
Crawford JS. Conservative management of cataracts. Int Ophthalmol Clin. 1977;17(4):31-35.
Gomollón F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017;11(1):3-25. doi:10.1093/ecco-jcc/jjw168
Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997;41(2):209-214. doi:10.1136/gut.41.2.209
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Atilla Bulur, Kamil Özdil, Nermin Mutlu Bilgiç, Kemal Kürbüz, Oğuzhan Öztürk, Zuhal Çalışkan, Süleyman Sayar, Roni Atalay, Hamdi Levent Doğanay
This work is licensed under a Creative Commons Attribution 4.0 International License.